É. Luporsi

1.6k total citations
66 papers, 1.0k citations indexed

About

É. Luporsi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, É. Luporsi has authored 66 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in É. Luporsi's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (11 papers) and Advanced Breast Cancer Therapies (8 papers). É. Luporsi is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (11 papers) and Advanced Breast Cancer Therapies (8 papers). É. Luporsi collaborates with scholars based in France, Belgium and United States. É. Luporsi's co-authors include S. Hoffstetter, D. Peiffert, M Pernot, Pierre Bey, Jacques Bonneterre, M. Lapeyre, M. Namer, P. Fumoleau, Thierry Conroy and P. Aletti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

É. Luporsi

60 papers receiving 969 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
É. Luporsi France 19 545 292 255 232 167 66 1.0k
C. Parsons United Kingdom 14 377 0.7× 349 1.2× 160 0.6× 223 1.0× 120 0.7× 42 912
Matthew M. Poppe United States 20 283 0.5× 203 0.7× 363 1.4× 244 1.1× 38 0.2× 54 940
R. L. Scotte Doggett United States 20 297 0.5× 440 1.5× 145 0.6× 864 3.7× 99 0.6× 26 1.3k
Mario Roncadin Italy 18 419 0.8× 210 0.7× 474 1.9× 347 1.5× 43 0.3× 64 1.1k
H.J. Dobbs United Kingdom 12 502 0.9× 457 1.6× 861 3.4× 286 1.2× 60 0.4× 23 1.5k
Talha Shaikh United States 15 288 0.5× 231 0.8× 151 0.6× 528 2.3× 95 0.6× 43 947
J Mesić United States 9 298 0.5× 432 1.5× 213 0.8× 1.5k 6.6× 190 1.1× 13 1.9k
RD Gelber United States 14 485 0.9× 249 0.9× 484 1.9× 378 1.6× 29 0.2× 35 1.6k
Hong Ryull Pyo South Korea 18 534 1.0× 274 0.9× 54 0.2× 603 2.6× 76 0.5× 38 1.4k
P. Foro Spain 15 373 0.7× 400 1.4× 222 0.9× 340 1.5× 78 0.5× 65 1.0k

Countries citing papers authored by É. Luporsi

Since Specialization
Citations

This map shows the geographic impact of É. Luporsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by É. Luporsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites É. Luporsi more than expected).

Fields of papers citing papers by É. Luporsi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by É. Luporsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by É. Luporsi. The network helps show where É. Luporsi may publish in the future.

Co-authorship network of co-authors of É. Luporsi

This figure shows the co-authorship network connecting the top 25 collaborators of É. Luporsi. A scholar is included among the top collaborators of É. Luporsi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with É. Luporsi. É. Luporsi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albuisson, Éliane, et al.. (2018). Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation. Familial Cancer. 18(1). 1–8. 5 indexed citations
2.
Luporsi, É., et al.. (2018). PALB2, gène majeur de susceptibilité au cancer du sein. Gynécologie Obstétrique Fertilité & Sénologie . 46(10-11). 701–705. 4 indexed citations
3.
Bidard, François‐Clément, Étienne Brain, William Jacot, et al.. (2016). First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count. Annals of Oncology. 27. vi69–vi69. 1 indexed citations
4.
5.
Luporsi, É., Jean‐François Morère, Florian Scotté, et al.. (2013). Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis). Value in Health. 16(3). A112–A112. 1 indexed citations
6.
7.
Rousseau, Frédérique, F. Rétornaz, Florence Joly, et al.. (2010). Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO). Critical Reviews in Oncology/Hematology. 76(1). 71–78. 9 indexed citations
8.
Fumoleau, P., Henri Roché, Pierre Kerbrat, et al.. (2005). Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results. Annals of Oncology. 17(1). 85–92. 81 indexed citations
9.
Bernier‐Chastagner, Valérie, Jacques Grill, François Doz, et al.. (2005). Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas. Cancer. 104(12). 2792–2797. 60 indexed citations
10.
11.
Conroy, Thierry, M. Mercier, Jacques Bonneterre, et al.. (2004). French version of FACT-G: validation and comparison with other cancer-specific instruments. European Journal of Cancer. 40(15). 2243–2252. 59 indexed citations
12.
Hoffstetter, S., C. Marchal, É. Luporsi, et al.. (2004). Curiethérapie préopératoire des adénocarcinomes de l'endomètre de stades cliniques I–II : résultats à dix ans d'une série de 780 patientes. Cancer/Radiothérapie. 8(3). 178–187. 1 indexed citations
13.
Andrieu, Nadine, Teresa C. Prevost, É. Luporsi, et al.. (2000). Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality. International Journal of Epidemiology. 29(2). 214–223. 32 indexed citations
14.
Charra-Brunaud, C., D. Peiffert, S. Hoffstetter, et al.. (1998). Curiethérapie vaginale postopératoire des adénocarcinomes de l'endomètre à bas débit de dose. Cancer/Radiothérapie. 2(1). 34–41. 6 indexed citations
15.
Andrieu, Nadine, Teresa Smith, Stephen W. Duffy, et al.. (1998). The effects of interaction between familial and reproductive factors on breast cancer risk: a combined analysis of seven case-control studies. British Journal of Cancer. 77(9). 1525–1536. 15 indexed citations
16.
Marchal, C., et al.. (1996). Particularités diagnostiques et thérapeutiques du cancer du sein de la femme âgée. Groupe Sein du Centre Alexis Vautrin.. La Presse Médicale. 25(34). 1 indexed citations
17.
Meunier, Alice, et al.. (1996). [Axillary lymphoceles after breast cancer surgery. Pathogeny, prevention].. PubMed. 133(9-10). 448–52. 3 indexed citations
18.
Pernot, M, S. Hoffstetter, D. Peiffert, et al.. (1995). Etude statistique d'une serie de 672 carcinomes du col uterin. Resultats et complications selon l'age et les modalites de traitement. Bulletin du Cancer. 82(82). 568–581. 12 indexed citations
19.
Andrieu, Nadine, et al.. (1995). Familial risk, abortion and their interactive effect on the risk of breast cancer - a combined analysis of six case-control studies. British Journal of Cancer. 72(3). 744–751. 26 indexed citations
20.
Beauvois, Sylvie, et al.. (1994). Brachytherapy for lower lip epidermoid cancer: tumoral and treatment factors influencing recurrences and complications. Radiotherapy and Oncology. 33(3). 195–203. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Parsons Breakdown of academic impact, for papers by Matthew M. Poppe Breakdown of academic impact, for papers by R. L. Scotte Doggett Breakdown of academic impact, for papers by Mario Roncadin Breakdown of academic impact, for papers by H.J. Dobbs Breakdown of academic impact, for papers by Talha Shaikh Breakdown of academic impact, for papers by J Mesić Breakdown of academic impact, for papers by RD Gelber Breakdown of academic impact, for papers by Hong Ryull Pyo Breakdown of academic impact, for papers by P. Foro
Rankless by CCL
2026